Urology

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Colquhoun AJ et al. - Non-muscle-invasive (NMI) transitional cell carcinoma (TCC) of the bladder is a common disease that recurs frequently and may progress to more sinister invasive disease. In the absence of a molecular tool that can accurately predict an individual's propensity to tumour recurrence and/or progression, urologists utilise prognostic factors to predict patient outcome. The data obtained regarding prognostic factors are used to describe a rationale follow-up schedule for patients with NMI TCC of the bladder.


Today in Bladder...keeping you current

Randomized phase III trial on gemcitabine versus mytomicin in recurrent superficial bladder cancer: Evaluation of efficacy and tolerance
Journal of Clinical Oncology, 10/26/09

Fesoterodine: a new antimuscarinic for overactive bladder
Aging Health, 10/13/09

Frequently asked questions in the evaluation and management of overactive bladder
The Journal of Family Practice, 11/02/09

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Send this Summary to a Colleague

Enter email address